Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas
Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC ( Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas )
17 Jul 2025

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
11 Jul 2025

Independent clones in CLL show oligoclonality and early evolution patterns

Dr Ferran Nadeu - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
Independent clones in CLL show oligoclonality and early evolution patterns ( Dr Ferran Nadeu - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain )
10 Jul 2025

Breast cancer survivorship

Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg
Breast cancer survivorship ( Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg )
10 Jul 2025

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi
Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )
10 Jul 2025

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )
9 Jul 2025

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

Dr Ricky Frazer and Dr Rebecca Dobson
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective ( Dr Ricky Frazer and Dr Rebecca Dobson )
7 Jul 2025

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia

Dr Anthony Stein - City of Hope, Duarte, USA
Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )
27 Jun 2025

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )
27 Jun 2025

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )
27 Jun 2025

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )
27 Jun 2025

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
27 Jun 2025